These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 31846828)

  • 1. Development of selective mono or dual PROTAC degrader probe of CDK isoforms.
    Zhou F; Chen L; Cao C; Yu J; Luo X; Zhou P; Zhao L; Du W; Cheng J; Xie Y; Chen Y
    Eur J Med Chem; 2020 Feb; 187():111952. PubMed ID: 31846828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML.
    Wu M; Wang W; Mao X; Wu Y; Jin Y; Liu T; Lu Y; Dai H; Zeng S; Huang W; Wang Y; Yao X; Che J; Ying M; Dong X
    Eur J Med Chem; 2024 Sep; 275():116539. PubMed ID: 38878515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7).
    Ji W; Du G; Jiang J; Lu W; Mills CE; Yuan L; Jiang F; He Z; Bradshaw GA; Chung M; Jiang Z; Byun WS; Hinshaw SM; Zhang T; Gray NS
    Eur J Med Chem; 2024 Oct; 276():116613. PubMed ID: 39004018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective degradation of CDK6 by a palbociclib based PROTAC.
    Rana S; Bendjennat M; Kour S; King HM; Kizhake S; Zahid M; Natarajan A
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1375-1379. PubMed ID: 30935795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule degraders of cyclin-dependent kinase protein: a review.
    Yu B; Du Z; Zhang Y; Li Z; Bian J
    Future Med Chem; 2022 Jan; 14(3):167-185. PubMed ID: 34939427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies.
    Kumarasamy V; Gao Z; Zhao B; Jiang B; Rubin SM; Burgess K; Witkiewicz AK; Knudsen ES
    Br J Cancer; 2023 Oct; 129(8):1238-1250. PubMed ID: 37626264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.
    Hati S; Zallocchi M; Hazlitt R; Li Y; Vijayakumar S; Min J; Rankovic Z; Lovas S; Zuo J
    Eur J Med Chem; 2021 Dec; 226():113849. PubMed ID: 34560429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
    King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
    Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2.
    Riching KM; Schwinn MK; Vasta JD; Robers MB; Machleidt T; Urh M; Daniels DL
    SLAS Discov; 2021 Apr; 26(4):560-569. PubMed ID: 33190579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
    Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
    Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities.
    Zhang X; Wang W; Dong G; Song Y; Zhai X; Sheng C
    Bioorg Med Chem Lett; 2024 Sep; 109():129838. PubMed ID: 38838918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Degraders of Cyclin-Dependent Kinases
    He H; Zhang X; Wang J; Liu Q; Zhang L; Chen L; Yuan Y; Zhao Z; Li H; Chen Z
    J Med Chem; 2024 Jul; 67(13):11354-11364. PubMed ID: 38943626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of selective degraders of EGFR
    Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
    Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
    Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
    Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation.
    Chen H; Chen F; Pei S; Gou S
    Bioorg Chem; 2019 Jun; 87():191-199. PubMed ID: 30901674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
    Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
    Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
    Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.